EnterNext welcomes Cerenis Therapeutics on Euronext in Paris
30/03/2015
Jean-Louis Dasseux, President and CEO of Cerenis Therapeutics, rings the opening bell.
Cerenis Therapeutics is specialized in research & development into HDL therapies (High Density lipoproteins) intended for the treatment of cardiovascular and metabolic disorders. HDLs, also known as good cholesterol, are fat and protein complexes that contribute to the transportation of cholesterol from the body's tissues to the liver and are linked to a decrease in the risk of atherosclerosis and coronary diseases.
At the end of 2014, the firm boasted a portfolio of 6 products, with 3 in pre-clinical development and 3 in phase I of clinical development.